Abbott Laboratories stock jumped nearly 11% after posting second-quarter results that topped expectations and lifting its full-year earnings forecast, signaling confidence in its execution.

The Numbers

Abbott reported adjusted diluted earnings per share of $1.31 for the second quarter, beating analyst expectations of $1.28. Revenue landed at $12.59 billion, up 13% on a reported basis compared to the same quarter last year. On a comparable basis—which strips out the impact of acquisitions and currency swings—revenue growth was 4.8%.

Guidance Raised

The company raised its full-year adjusted EPS guidance to $5.45 to $5.60, up from its prior range of $5.38 to $5.58. That upward revision reflects management's confidence that the company can sustain its operational momentum through year-end.

Capital Returned

Abbott returned $2.1 billion to shareholders during the quarter through dividends and stock buybacks. For long-term investors, this signals the company's commitment to returning cash while still funding growth initiatives and maintaining financial flexibility.

What It Means

Abbott's beat and raised guidance suggest solid operational execution across its portfolio. The earnings beat was three cents per share, and revenue exceeded expectations. The stock's 11% surge reflects investor confidence that guidance remains on track and the company is executing. For buy-and-hold investors, the combination of earnings growth, dividend consistency, and capital returns matter more than any single quarter's surprise.